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Tuesday, March 8, 2011 371acontractility through modulating molecular conformation and function of the
core structure of cTnI.
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Heart muscle has been considered to contain predominantly a-Tm (TPM1
gene). However this has not been investigated with tools that can clearly
distinguish all tropomyosin isoforms. We initially used LC/MS to character-
ise the isoforms present in Tm purified from human heart muscle. Mass
spectroscopy of Tm purified from human donor heart showed two dominant
species, a 32754 Da peak, corresponding to acetylated a-Tm and a 32867
Da peak. The second peak was putatively identified by its mass as g-Tm.
These identities were confirmed by comparison with pure recombinant
a and g-skeletal tropomyosin expressed in the baculovirus/sf9 system (sup-
plied by Dr Kristen Nowak, University Western Australia). The novel Tm is
slow-skeletal Tm from the TPM3 gene, also known as g-skeletal tropomy-
osin, (theoretical mass 32859.0 Da). Only very low levels (<5%) of k Tm
or of phosphorylated Tm were detected. Analysis of samples from failing
heart muscle and in myectomy samples showed significantly reduced g-
Tm levels.
The identity of the isoforms characterised in human heart was confirmed by
urea SDS-PAGE, which can separate the two species, and the use of
isoform-specific antibodies. Using the pure recombinant Tms, we demonstrated
that monoclonal antibody CG3 was specific for the g isoform, CH291 was spe-
cific for the a isoform and CH1 did not distinguish between the two isoforms.
Western blotting with these specific antibodies confirmed significant quantities
of g-Tm and a-Tm in both human and mouse hearts. In mice, the level of g-Tm
depends on the strain, being around 50% in many strains, but low in FVB/N
mice.
This discovery is functionally significant as in vitro motility assays using pure
g-Tm and a-Tm shows significant differences between the isoforms.
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Alpha-adrenergic receptor activated protein kinase Ca (PKCa) modifies
cardiac contractile function and is implicated in heart failure. Aim of
the study: To determine the specific effects of PKCa-mediated phosphor-
ylation of cardiac troponin (cTn) on myofilament function in failing cardi-
omyocytes. Methods: Endogenous cTn in Triton-permeabilized
cardiomyocytes from patients with end-stage idiopathic dilated cardiomyop-
athy was partially exchanged (~69%) with PKCa-treated recombinant hu-
man cTn(DD), in which the PKA-sites Ser23/24 on cTnI were mutated
into aspartic acids (D). cTn(DD) was used to rule out in-vitro cross-phos-
phorylation of the PKA-sites by PKCa. A comparison was made between
the effects of PKCa-treated and untreated cTn(DD). Isometric force was
measured at various [Ca2þ] to determine the maximum isometric force
per cross-sectional area (Fmax) and the calcium sensitivity of force
(pCa50). Results: Fmax after exchange with PKCa-treated cTn(DD)
(17.151.9 kN/m2) was significantly reduced in comparison with untreated
cTn(DD) (26.151.9 kN/m2). Subsequent incubation of the cardiomyocytes
with activated PKCa in the PKCa-treated cTn(DD) group did not restore
Fmax. Cardiomyocytes exchanged with PKCa-treated cTn(DD) were moresensitive to Ca2þ (pCa50=5.5950.02) than cells exchanged with untreated
cTn(DD) (pCa50=5.5150.02). Surprisingly, subsequent PKCa-incubation
of cardiomyocytes exchanged with PKCa-treated cTn(DD) caused a reduc-
tion in pCa50 to 5.4550.02. Western blot analysis of PKCa-treated cTn
showed phosphorylation of Ser42 and Thr143 on cTnI. Mass spectrometry
revealed two novel phosphorylation sites: Ser198 on cTnI and Ser179 on
cTnT. Conclusions: Specific in vitro PKCa-mediated phosphorylation of
cTn increases Ca2þ-sensitivity and decreases maximal force. Subsequent
PKCa-mediated phosphorylation of the myofilaments in situ decreases
Ca2þ-sensitivity, without affecting Fmax. These results demonstrate the
dual, site-specific effects of PKCa-mediated phosphorylation in human
myocardium.Platform AV: Protein Conformation
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Protein unfolding, disassembly, and aggregation underlie many diseases, but
detailed study of these processes in intact cells has been limited. Cysteine
Shotgun labeling utilizes cell-permeable fluorescent dyes to label exposed
cysteine residues and was initially applied to study protein structure changes
in response to mechanical stress on cells. We have re-purposed the tech-
nique to identify protein changes in whole-cell lysates in native versus
urea-denaturing conditions and in live cells all as a function of time and
temperature (20-45 deg-C). Labeling rate constants are calculated for any
given Cys site by normalizing the protein labeling kinetics to the rapid la-
beling under denaturing conditions. Proteins can be identified and further
analyzed by mass spectrometry to pinpoint specific, susceptible domains in-
volved. A number of proteins contain cys with a wide variety of rate con-
stants. These proteins include structural proteins such as Filamin A and B,
Talin 1, Myosin 9 and alpha-actinin-4, heat shock protein 1 and elongation
factor 2. Some of these various proteins contain many cysteine-rich domains
and thus appear especially amenable to studying by this new in-cell
technique.
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Fibronectin is an extracellular matrix protein that is assembled by fibroblasts
into fibrils. Previous studies have shown that fibronectin fibrils are extremely
elastic: cells can stretch them up to four times their resting length. The
mechanism of this elasticity has been debated. Some have hypothesized
that unfolding of the 15 Type III domains, each of which are a 7-beta strand
sandwich, drives fibril elasticity. Others have hypothesized that the elasticity
is driven by a conformational change of the entire fibronectin molecule from
a compact to an extended form, without unfolding of Type III domains.
Here we have investigated the unfolding of Type III domains in stretched
fibrils by fluorescent labeling of buried free thiols. We generated a library
of recombinant fibronectins, each of which had a single buried free thiol
in a different Type III domain. Fibronectin matrices containing these re-
combinant fibronectins were labeled with a thiol reactive fluorescent probe;
successful labeling indicated that the domain was unfolded to expose the
buried free thiol, while no labeling suggested that the domain remained
folded. Thiol labeling experiments were also conducted on fibronectin in so-
lution, as some Type III domains have previously been shown to unfold and
refold in the absence of applied tension. Data indicates that Type III do-
mains can be categorized into three groups based on their unfolding proper-
ties: nine (9) Type III domains showed no evidence of unfolding in either
fibrils or solution; four (4) domains showed evidence of unfolding in both
fibrils and in solution; and two (2) domains showed evidence of unfolding
exclusively in fibrils. These results suggest that there is a subset of Type
III domains that unfold within fibronectin that may play a role in fibronectin
fibril elasticity.
